Candesartan in the treatment of hypertension: what have we learnt in the last decade?

被引:6
作者
Barrios, Vivencio [1 ]
Escobar, Carlos [2 ]
机构
[1] Hosp Ramon & Cajal, Dept Cardiol, E-28034 Madrid, Spain
[2] Hosp Infanta Sofia, Dept Cardiol, Madrid, Spain
关键词
blood pressure; candesartan; efficacy; heart failure; hypertension; left ventricular hypertrophy; microalbuminuria; safety; LEFT-VENTRICULAR HYPERTROPHY; CHRONIC HEART-FAILURE; BLOCKER-BASED REGIMEN; CONVERTING-ENZYME INHIBITORS; BLOOD-PRESSURE CONTROL; CARDIOVASCULAR RISK; DOUBLE-BLIND; ANGIOTENSIN RECEPTORS; COMBINATION THERAPY; CLINICAL-PRACTICE;
D O I
10.1517/14740338.2011.608064
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Although all of the first-line antihypertensive drugs effectively reduce blood pressure, there are some conditions that may favor the use of angiotensin receptor blockers over others, such as left ventricular hypertrophy, microalbuminuria, renal dysfunction, diabetes, or metabolic syndrome, among others. Areas covered: This manuscript reviewed the data supporting the use of candesartan cilexetil in hypertensive population with a special focus on its efficacy and safety. For this purpose, a search on MEDLINE and EMBASE databases was performed. The MEDLINE and EMBASE search included both medical subject headings (MeSH) and keywords including: candesartan OR angiotensin receptor blockers OR renin angiotensin system AND hypertension treatment. References of the retrieved articles were also screened for additional studies. There were no language restrictions. Expert opinion: Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective and well-tolerated therapy in the entire spectrum of hypertensive patients, including those at higher risk, such as those with diabetes, metabolic syndrome, left ventricular hypertrophy, or microalbuminuria.
引用
收藏
页码:957 / 968
页数:12
相关论文
共 54 条
[51]   A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II [J].
Vidt, DG ;
White, WB ;
Ridley, E ;
Rahman, M ;
Harris, S ;
Vendetti, J ;
Michelson, EL ;
Wang, R .
JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (07) :475-480
[52]   Outpatient hypertension treatment, treatment intensification, and control in western Europe and the United States [J].
Wang, Y. Richard ;
Alexander, G. Caleb ;
Stafford, Randall S. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (02) :141-147
[53]   Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:: the CHARM-Preserved Trial [J].
Yusuf, S ;
Pfeffer, MA ;
Swedberg, K ;
Granger, CB ;
Held, P ;
McMurray, JJV ;
Michelson, EL ;
Olofsson, B ;
Östergren, J .
LANCET, 2003, 362 (9386) :777-781
[54]   A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension [J].
Zheng, Zhenfeng ;
Shi, Huilan ;
Jia, Junya ;
Li, Dong ;
Lin, Shan .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2011, 12 (03) :365-374